Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study.

Autor:	Di Pierro F; Scientific & Research Department, Velleja Research, Milan, Italy.; Digestive Endoscopy, Fondazione Poliambulanza, Brescia, Italy., Derosa G; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.; Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy., Maffioli P; Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy., Bertuccioli A; Department of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy., Togni S; Indena Research and Development Department, Milan, Italy., Riva A; Indena Research and Development Department, Milan, Italy., Allegrini P; Indena Research and Development Department, Milan, Italy., Khan A; Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK.; University of Health Sciences, Lahore, Pakistan., Khan S; Department of Molecular Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Khan BA; Department of Molecular Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Altaf N; Department of Molecular Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Zahid M; Department of Molecular Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Ujjan ID; Department of Pathology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan., Nigar R; Department of Obstetrics and Gynaecology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan., Khushk MI; Department of Pathology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan., Phulpoto M; Department of Obstetrics and Gynaecology, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan., Lail A; Department of Paediatric Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Devrajani BR; Department of Medicine, Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan., Ahmed S; Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
Jazyk:	angličtina
Zdroj:	International journal of general medicine [Int J Gen Med] 2021 Jun 08; Vol. 14, pp. 2359-2366. Date of Electronic Publication: 2021 Jun 08 (Print Publication: 2021).
DOI:	10.2147/IJGM.S318720
Abstrakt:	Background: Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome ® , QP) increases its oral absorption up to 20-fold. Methods: In the present prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of QP was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease. Results: The results revealed a reduction in frequency and length of hospitalization, in need of non-invasive oxygen therapy, in progression to intensive care units and in number of deaths. The results also confirmed the very high safety profile of quercetin and suggested possible anti-fatigue and pro-appetite properties. Conclusion: QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease. It is suggested that a double-blind, placebo-controlled study should be urgently carried out to confirm the results of our study. Competing Interests: FDP is a member of the Scientific Board of Pharmextracta. AB provided scientific advice to Pharmextracta S.p.A. PA, ST and AR are employees of and belong to the Scientific Board of Indena. AR reports a pending patent WO2019016146A1 for quercetin phytosome. The authors report no other conflicts of interest in this work. (© 2021 Di Pierro et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu